Literature DB >> 8689188

Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study.

A Ortiz1, L F Martinez de Haro, P Parrilla, G Morales, J Molina, J Bermejo, R Liron, J Aguilar.   

Abstract

The results obtained for the treatment of 59 patients diagnosed with Barrett's oesophagus, randomized to receive medical treatment (n = 27) or antireflux surgery (n = 32) were assessed prospectively. Median follow-up for the patients undergoing medical treatment was 4 (range 1-11) years and for patients undergoing surgical treatment 5 (range 1-11) years. Satisfactory symptomatic control (excellent to good results) was achieved in 24 patients after medical therapy and in 29 after antireflux surgery. The proportion of patients with persistent inflammatory lesions (54 per cent) and persistent or recurrent stenosis (47 per cent) was significantly higher after conservative treatment than after surgery (5 and 15 per cent, respectively). A decrease in the length of the segment of columnar mucosa was observed in eight of the patients who underwent antireflux surgery, and in only two of those given medical therapy. Conversely, an upward progression of the columnar lining was more frequent in the latter group (11 versus three). Mild dysplasia was observed in five patients, all from the group undergoing medical treatment. Severe dysplasia was detected in two patients, one undergoing medical treatment and the other following surgical therapy, in whom an antireflux procedure had failed previously. Both patients underwent oesophageal resection, with confirmation of a carcinoma in situ. The patients in whom antireflux surgery proved effective showed no dysplastic change or progression to adenocarcinoma. These results, despite the small number of patients and methodological limitations, question the systematic conservative approach in the initial management of patients with Barrett's oesophagus.

Entities:  

Mesh:

Year:  1996        PMID: 8689188

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  49 in total

Review 1.  Barrett's oesophagus.

Authors:  R M Navaratnam; M C Winslet
Journal:  Postgrad Med J       Date:  1998-11       Impact factor: 2.401

Review 2.  Antireflux surgery in the management of Barrett's esophagus.

Authors:  T R DeMeester
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

3.  [Laparoscopic fundoplication. Indications and results].

Authors:  K H Fuchs; H Feussner
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

4.  Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus.

Authors:  Pascual Parrilla; Luisa F Martínez de Haro; Angeles Ortiz; Vicente Munitiz; Joaquín Molina; Juan Bermejo; Manuel Canteras
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

5.  Barrett's esophagus: now what?

Authors:  Jeffrey H Peters
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

Review 6.  Barrett's esophagus with high-grade dysplasia: focus on current treatment options.

Authors:  Leonidas Lekakos; Nikolaos P Karidis; Dimitrios Dimitroulis; Christos Tsigris; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

7.  Early and late results of the acid suppression and duodenal diversion operation in patients with barrett's esophagus: analysis of 210 cases.

Authors:  Attila Csendes; Patricio Burdiles; Italo Braghetto; Owen Korn; Juan Carlos Díaz; Jorge Rojas
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

Review 8.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

Review 9.  How should Barrett's ulceration be treated?

Authors:  J H Peters; K K Wang
Journal:  Surg Endosc       Date:  2004-01-12       Impact factor: 4.584

10.  Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. Protagonist.

Authors:  L Lundell
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.